Praxis Precision Medicines, Inc. 8-K

What Happened Praxis Precision Medicines, Inc. filed an 8-K on June 12, 2026 reporting the results of its Annual Meeting of Stockholders held June 10, 2026. Stockholders elected three Class III directors — Gregory Norden, Marcio Souza and William Young — to serve until the 2029 annual meeting. Shareholders also ratified Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal year 2026 and approved, on an advisory (non-binding) basis, the compensation of the company’s named executive officers.

Key Details

• Director elections (Class III terms to 2029):
  • Gregory Norden: 24,597,327 votes for; 310,937 withheld; 1,815,967 broker non-votes.
  • Marcio Souza: 24,771,396 votes for; 136,868 withheld; 1,815,967 broker non-votes.
  • William Young: 21,293,535 votes for; 3,614,729 withheld; 1,815,967 broker non-votes.
• Auditor ratification: Ernst & Young LLP ratified as independent auditor for fiscal 2026 — 26,667,376 for; 39,285 against; 17,570 abstain.
• Advisory vote on executive compensation (say-on-pay): Approved — 24,054,017 for; 824,318 against; 29,929 abstain; 1,815,967 broker non-votes.
• No other matters were voted on at the meeting.

Why It Matters The results confirm the current board slate and continuity of corporate governance through 2029 for the elected directors. Ratifying Ernst & Young LLP provides continuity for the company’s financial audits for fiscal 2026. The advisory approval of executive compensation signals shareholder support for the company’s pay practices (though the vote is non-binding). Investors may note the notable number of withheld votes for one director and the presence of broker non-votes, which reflect shares that were not voted on certain proposals.